The linkage of vascular genes to specific functions will lead to a better understanding of cardiovascular pathophysiology. We developed an experimental model that enables the introduction of one or multiple gene(s) into vascular smooth muscle cells (VSMCs) of isolated resistance arteries. Exposure of the arteries to a green fluorescent protein (GFP)-encoding plasmid in combination with the transfectant Effectene® for 20 h resulted in the expression of GFP in virtually all VSMCs in the arterial wall at fully preserved vascular function. For functional validation of the model, plasmids encoding the specific RhoA inhibitors C3 transferase or N19RhoA were transfected. In subsequent functional tests, inhibition of RhoA-dependent constriction induced by sphingosine-1-phosphate was similar to that in arteries treated with exogenous C3 transferase protein or the Rho kinase inhibitor Y27632. Responses to norepinephrine remained unaffected. This novel transfection technique enables gene function to be assessed in direct conjunction with signalling pathways in vascular tissue and provides, therefore, a new tool for microvascular proteomics.

Keywords:
Hypertension, Plasmids, Rho kinase, RhoA, Transfection
1.
Fairchild TA, Fulton D, Fontana JT, et al: Acidic hydrolysis as a mechanism for the cleavage of the Glu(298)–>Asp variant of human endothelial nitric-oxide synthase. J Biol Chem 2001;276:26674–26679.
2.
Kaiser S, Toborek M: Liposome-mediated high-efficiency transfection of human endothelial cells. J Vasc Res 2001;38:133–143.
3.
Huang QQ, Fisher SA, Brozovich FV: Forced expression of essential myosin light chain isoforms demonstrates their role in smooth muscle force production. J Biol Chem 1999;274:35095–35098.
4.
Maasch C, Wagner S, Lindschau C, et al: Protein kinase Cα targeting is regulated by temporal and spatial changes in intracellular free calcium concentration [Ca(2+)](i). FASEB J 2000;14:1653–1663.
5.
Seki N, Hashimoto N, Suzuki Y, et al: Role of SRC homology 2-containing tyrosine phosphatase 2 on proliferation of rat smooth muscle cells. Arterioscler Thromb Vasc Biol 2002;22:1081–1085.
6.
Sekine O, Nishio Y, Egawa K, et al: Insulin activates CCAAT/enhancer binding proteins and proinflammatory gene expression through the phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells. J Biol Chem 2002;277:36631–36639.
7.
Vajanto I, Rissanen TT, Rutanen J, et al: Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ. J Gene Med 2002;4:371–380.
8.
Vassalli G, Agah R, Qiao R, et al: A mouse model of arterial gene transfer: Antigen-specific immunity is a minor determinant of the early loss of adenovirus-mediated transgene expression. Circ Res 1999;85:e25–e32.
9.
Bolz SS, Pieperhoff S, de Wit C, et al: Intact endothelial and smooth muscle function in small resistance arteries after 48 h in vessel culture. Am J Physiol 2000;279:H1434–H1439.
10.
Aktories K, Hall A: Botulinum ADP-ribosyltransferase C3: A new tool to study low molecular weight GTP-binding proteins. Trends Pharmacol Sci 1989;10:415–418.
11.
Qiu RG, Chen J, McCormick F, et al: A role for Rho in Ras transformation. Proc Natl Acad Sci USA 1995;92:11781–11785.
12.
Bolz SS, de Wit C, Pohl U: Endothelium-derived hyperpolarizing factor but not NO reduces smooth muscle Ca2+ during acetylcholine-induced dilation of microvessels. Br J Pharmacol 1999;128:124–134.
13.
Bolz SS, Fisslthaler B, Pieperhoff S, et al: Antisense oligonucleotides against cytochrome P450 2C8 attenuate EDHF-mediated Ca(2+) changes and dilation in isolated resistance arteries. FASEB J 2000;14:255–260.
14.
Motulsky HJ, Ransnas LA: Fitting curves to data using nonlinear regression: A practical and nonmathematical review. FASEB J 1987;1:365–374.
15.
Shin HM, Je HD, Gallant C, et al: Differential association and localization of myosin phosphatase subunits during agonist-induced signal transduction in smooth muscle. Circ Res 2002;90:546–553.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.